FOAMIX PHARMACEUTICALS LTD (FOMX) Covered Calls

You can sell covered calls on FOAMIX PHARMACEUTICALS LTD to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for FOMX (prices last updated Mon 11:50 AM ET):

FOAMIX PHARMACEUTICALS LTD (FOMX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
5.06 -0.08 5.03 5.06 95K - 0.2B
Covered Calls For FOAMIX PHARMACEUTICALS LTD (FOMX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 5 0.70 4.36 14.7% 206%
Dec 21 5 0.70 4.36 14.7% 88.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.